Head and Neck Cancer Therapeutics: Global Markets
Description
Head and Neck Cancer Therapeutics: Global Markets
Report Scope:
This report aims to provide a comprehensive study of the global market for head and neck cancer therapeutics, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding head and neck cancer therapeutic drugs.
An in-depth analysis of the global head and neck cancer therapeutics market includes historical data and market projections on sales by type of diagnostic method, treatment type, disease indication, route of administration, therapeutic class, and end user. It describes the different types of head and neck cancers (lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer) and their current and historical market revenues. This report also categorizes the global head and neck cancer therapeutics market based on the route of administration (injectable and oral).
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market shares. The report also discusses pipeline analysis and the new regulatory landscape of the drugs marketed.
Report Includes:
64 data tables and 17 additional tables
A comprehensive overview of the global markets for head and neck cancer therapeutics within the industry
Analyses of the global market trends, with historic market revenue data for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Estimation and forecast the actual market size for head and neck cancer therapeutics, and corresponding market share analysis by diagnostic method, treatment type, disease indication, route of administration, therapeutic class, end-user, and region
Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on COVID-19 impact on the head and neck cancer therapeutics market
Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on new products development, regulatory scenario, and reimbursement and pricing factors
In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, and major types of end-user markets
Market share analysis of the key market participants in the global pharmaceuticals industry, their research priorities, product portfolios, pipeline products, and company competitive landscape
Descriptive company profiles of the leading global players, including AstraZeneca plc, Bristol-Myers Squibb, Eli Lilly and Co., Sanofi S.A., Merck & Co., and Pfizer Inc.
Companies Mentioned
Abbvie Inc.
Astrazeneca Plc
Bayer Ag
Bristol-myers Squibb
Eli Lilly And Co.
F. Hoffmann-la Roche Ltd.
Merck & Co.
Pfizer Inc.
Sanofi-aventis
Report Scope:
This report aims to provide a comprehensive study of the global market for head and neck cancer therapeutics, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding head and neck cancer therapeutic drugs.
An in-depth analysis of the global head and neck cancer therapeutics market includes historical data and market projections on sales by type of diagnostic method, treatment type, disease indication, route of administration, therapeutic class, and end user. It describes the different types of head and neck cancers (lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer) and their current and historical market revenues. This report also categorizes the global head and neck cancer therapeutics market based on the route of administration (injectable and oral).
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market shares. The report also discusses pipeline analysis and the new regulatory landscape of the drugs marketed.
Report Includes:
64 data tables and 17 additional tables
A comprehensive overview of the global markets for head and neck cancer therapeutics within the industry
Analyses of the global market trends, with historic market revenue data for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Estimation and forecast the actual market size for head and neck cancer therapeutics, and corresponding market share analysis by diagnostic method, treatment type, disease indication, route of administration, therapeutic class, end-user, and region
Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on COVID-19 impact on the head and neck cancer therapeutics market
Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on new products development, regulatory scenario, and reimbursement and pricing factors
In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, and major types of end-user markets
Market share analysis of the key market participants in the global pharmaceuticals industry, their research priorities, product portfolios, pipeline products, and company competitive landscape
Descriptive company profiles of the leading global players, including AstraZeneca plc, Bristol-Myers Squibb, Eli Lilly and Co., Sanofi S.A., Merck & Co., and Pfizer Inc.
Companies Mentioned
Abbvie Inc.
Astrazeneca Plc
Bayer Ag
Bristol-myers Squibb
Eli Lilly And Co.
F. Hoffmann-la Roche Ltd.
Merck & Co.
Pfizer Inc.
Sanofi-aventis
Table of Contents
148 Pages
- Chapter 1 Introduction
- 1.1 Study Goals and Objectives
- 1.2 Scope of Report
- 1.3 Methodology and Information Sources
- 1.4 Geographic Breakdown
- 1.5 Analyst's Credentials
- 1.6 BCC Custom Research
- 1.7 Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Market and Technology Background
- 3.1 Head and Neck Cancer Overview
- 3.2 Incidence
- 3.3 Stages of Head and Neck Cancer
- 3.4 Risk Factors
- 3.4.1 Alcohol and Tobacco Usage
- 3.4.2 Occupational Exposure
- 3.4.3 Radiation Exposure
- 3.4.4 Gender
- 3.4.5 Human Papillomavirus Infection (HPV)
- 3.5 Symptoms
- 3.6 Blockbuster Drugs
- 3.6.1 Erbitux (Cetuximab)
- 3.6.2 Taxotere (Docetaxel)
- 3.6.3 Keytruda (Pembrolizumab)
- 3.6.4 Opdivo (Nivolumab)
- 3.6.5 Hydrea (Hydroxyurea)
- Chapter 4 Regulatory Structure
- 4.1 Regulatory Challenges for Selected Countries
- 4.1.1 United States
- 4.1.2 Canada
- 4.1.3 Europe
- 4.1.4 Japan
- 4.1.5 India
- 4.1.6 Brazil
- Chapter 5 Market Breakdown, by Diagnostic Method
- 5.1 Diagnostic Methods
- 5.1.1 Biopsy
- 5.1.2 Imaging
- 5.1.3 Endoscopy
- 5.1.4 Other Diagnostic Methods
- Chapter 6 Market Breakdown, by Treatment Type
- 6.1 Overview
- 6.2 Treatment Types
- 6.2.1 Surgery
- 6.2.2 Radiation Therapy
- 6.2.3 Chemotherapy
- 6.2.4 Immunotherapy
- 6.2.5 Targeted Therapy
- Chapter 7 Market Breakdown, by Disease Indication
- 7.1 Overview
- 7.2 Disease Indications
- 7.2.1 Lip and Oral Cavity Cancer
- 7.2.2 Laryngeal Cancer
- 7.2.3 Oropharyngeal Cancer
- 7.2.4 Salivary Gland Cancer
- 7.2.5 Nasopharyngeal Cancer
- 7.2.6 Hypopharyngeal Cancer
- Chapter 8 Market Breakdown, by Route of Administration
- 8.1 Overview
- 8.2 Route of Administration
- 8.2.1 Injectable
- 8.2.2 Oral
- Chapter 9 Market Breakdown, by Therapeutic Class
- 9.1 Overview
- 9.2 Therapeutic Classes
- 9.2.1 PD Inhibitors
- 9.2.2 EGFR Inhibitors
- 9.2.3 Microtubule Inhibitors
- Chapter 10 Market Breakdown, by End User
- 10.1 Overview
- 10.2 End Users
- 10.2.1 Hospitals
- 10.2.2 Specialty Clinics
- 10.2.3 Ambulatory Surgical Centers
- 10.2.4 Others
- Chapter 11 Market Dynamics
- 11.1 Market Drivers
- 11.1.1 Immunotherapy against Autoimmune Disorders
- 11.1.2 Rising Incidence of Cancer Worldwide
- 11.1.3 Advances in Biochemistry and Genomics
- 11.1.4 High Unmet Need
- 11.2 Market Challenges
- 11.2.1 Lack of Oncology Professionals
- 11.2.2 High Cost of Biologic Therapies
- Chapter 12 Impact of COVID-19 on the Market
- 12.1 Overview
- 12.2 Impact of COVID-19 on Head and Neck Cancer Therapeutics
- 12.2.1 Delay in Surgeries
- 12.3 Trade Restrictions and Supply Disruptions
- Chapter 13 Pipeline Analysis
- 13.1 Overview
- Chapter 14 Competitive Landscape
- 14.1 Overview
- 14.2 Global Company Ranking
- Chapter 15 Company Profiles
- ABBVIE INC.
- ASTRAZENECA PLC
- BAYER AG
- BRISTOL-MYERS SQUIBB
- ELI LILLY AND CO.
- F. HOFFMANN-LA ROCHE LTD.
- PFIZER INC.
- MERCK & CO.
- SANOFI-AVENTIS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
